Dergiler / Turkish journal of emergency medicine (Online) / 2021 / Cilt: 21 - Sayı: 3

B‑type natriuretic peptide/ferritin ratio as a predictor of the risk of developing acute renal injury in acute decompensated heart failure

Sayfa
98–103
Yayın Tarihi
2022-11-02
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

CONCLUSION: The BNP/ferritin ratio is a new parameter that can be used to draw attention to the severity of the treatment and renal function in ADHF cases in emergency situations.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVES: Acute decompensated heart failure (ADHF) is a clinical condition that requires urgent diagnosis and treatment.
📊
Temel Bulgular & Veri:METHODS: A total of 157 patients with a diagnosis of ischemic dilated cardiomyopathy for more than 6 months that presented to our clinic with ADHF were included in this cohort study.
💡
Sonuç & Katkı:CONCLUSION: The BNP/ferritin ratio is a new parameter that can be used to draw attention to the severity of the treatment and renal function in ADHF cases in emergency situations.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVES: Acute decompensated heart failure (ADHF) is a clinical condition that requires urgent diagnosis and treatment. Patients present with pulmonary capillary wedge pressure, pulmonary arterial pressure, and venous pressure elevation. Along with the progressive deterioration observed in the clinical picture, impairment or deterioration of kidney function may also occur. In this study, we evaluated the B‑type natriuretic peptide(BNP)/ferritin ratio as a predictor of the risk of developing acute renal injury(ARI) in ADHF. METHODS: A total of 157 patients with a diagnosis of ischemic dilated cardiomyopathy for more than 6 months that presented to our clinic with ADHF were included in this cohort study. After the treatment protocol was applied, the sample was divided into two groups as patients with and without ARI. The BNP and ferritin levels were examined along with the routine blood parameters(BNP), and the BNP, ferritin, and BNP/ferritin values were compared between the groups. RESULTS: ARI was present in 34.3% (n = 54) of the patients, who were also found to have higher BNP (892.76 vs. 817.54), lower ferritin (86.78 ± 57.2 vs. 105.46 ± 38.3), and higher BNP/ ferritin (10.48 ± 2.14 vs. 7.89 ± 1.89). The multivariate logistic regression analysis revealed the BNP/ ferritin ratio as an independent risk factor for ARI (odds ratio = 3.19; 95% CI, 1.92‑6.54; P = 0.001). Using the receiver operating characteristic curve, a cutoff value of 9.32 for BNP/ferritin ratio had a sensitivity of 81.8% and a specificity of 93.5% (area under the curve 0.842, P < 0.001) for the prediction of ARI. CONCLUSION: The BNP/ferritin ratio is a new parameter that can be used to draw attention to the severity of the treatment and renal function in ADHF cases in emergency situations.

🔖

Bu Makaleye Atıf Yap

CEYHUN, G., ATEŞ, A., KÜÇÜKSU, Z., AYDIN, S. Ş., ÖZKOÇ, M., ALTINKAYA, O., ÖZTÜRK, M. (2022). B‑type natriuretic peptide/ferritin ratio as a predictor of the risk of developing acute renal injury in acute decompensated heart failure. Turkish journal of emergency medicine (Online), Cilt: 21 - Sayı: 3, 98–103. https://ajindex.com/articles/605210

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, IMPACT‑HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation management predischarge: Process for assessment of carvedilol therapy in heart failure (IMPACT‑HF) trial. J Am Coll Cardiol 2004;43:1534‑41
  2. Binanay C, Califf RM, Hasselblad V, O’Connor CO, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA 2005;294:1625‑33
  3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ,et al. 2016 ESC guidelines forthe diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2128‑200
  4. Fonarow GC, Adams KF Jr., Abraham WT, Yancy CW, Boscardin WJ, ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in‑hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005;293:572‑80
  5. Torre‑Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201‑6
  6. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta‑analysis. J Am Coll Cardiol 2008;52:818‑27
  7. O’Meara E, Murphy C, McMurray JJ. Anemia and heart failure. Curr Heart Fail Rep 2004;1:176‑82
  8. Consuegra‑Sánchez L, Núñez J, Fácila L, Bertomeu V, Robles R, Llácer A. Prognostic impact of anemia in acute heart failure. Rev Invest Clin 2006;58:279‑84
  9. Sánchez‑Torrijos J, Gudín‑Uriel M, Nadal‑Barangé M, Jacas‑Osborn V, Trigo‑Bautista A, Giménez‑Alcalá M, et al. Prognostic value of discharge hemoglobin level in patients hospitalized for acute heart failure. Rev Esp Cardiol 2006;59:1276‑82
  10. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure – Definition, outcome measures, animal models, fluid therapy and information technology needs: The second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004;8:R204‑12
  11. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC,et al. Importance of venous congestio